The Asia Pacific Urinalysis Test Market would witness market growth of 7.3% CAGR during the forecast period (2023-2029).
The rise in pregnancy rates in both developed and developing countries and rising awareness of the importance of regular medical checkups in developed nations will contribute to the industry's expansion in the years to come. The volume of tests will be driven by the need to protect pregnant women's safety and health. Also, among women who are more likely to have kidney impairment, fluctuations in hormone levels in pregnancy increase the risk of urinary tract infection. Moreover, serious pregnancy issues like preterm birth, high blood pressure, low birth weight, and severe preeclampsia can be brought on by UTIs.
Thus, preference for and advice from healthcare professionals regarding urine testing during pregnancy will accelerate the expansion of the urinalysis market in the years to come. It is anticipated that the introduction of portable, battery-operated urinalysis devices would open up new prospects for revenue generation for the producers of urinalysis goods due to the emerging countries' quick expansion and technological advancements in the in vitro diagnostics sector.
In 2011–12, about 11% of Australians aged 18 and up, or 1.7 million people, had biomedical signs of CKD, according to an analysis by the Australian Institute of Health and Welfare (AIHW) of the latest National Health Measures Survey (NHMS). The number of people with CKD rises quickly with age. About 44% of people aged 75 and up have it (AIHW 2018). Only 6.1% of NHMS respondents with biomedical signs of CKD said they had the disease. This shows that CKD is not diagnosed nearly as often as it should be. About 210,000 people in New Zealand have chronic kidney disease. This number is going up because there are so many people with diabetes. These factors are driving the market growth in the region.
The China market dominated the Asia Pacific Urinalysis Test Market by Country in 2022 and would continue to be a dominant market till 2029; thereby, achieving a market value of $496.1 Million by 2029. The Japan market is estimated to grow a CAGR of 6.5% during (2023 - 2029). Additionally, The India market would experience a CAGR of 8.3% during (2023 - 2029).
Based on Product, the market is segmented into Consumables and Instruments. Based on Application, the market is segmented into Disease Screening and Pregnancy & Fertility. Based on End User, the market is segmented into Diagnostic Laboratories, Hospitals & Clinics and Homecare. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Urinalysis Test Market is Projected to reach USD 4.8 Billion by 2029, at a CAGR of 6.3%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Cardinal Health, Inc., Siemens Healthineers AG (Siemens AG), ACON Laboratories, Inc., Sysmex Corporation, Bio-Rad Laboratories, Inc., Arkray, Inc., Abbott Laboratories, Danaher Corporation, F. Hoffmann-La Roche Ltd., and Becton, Dickinson and Company.
By Product
By Application
By End User
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
